Artificial Nucleosides, Nucleotides, Therapeutic Applications (EP3418289A1)

The European Patent Office published patent application EP3418289A1 for artificial nucleosides, artificial nucleotides, and artificial oligonucleotides with therapeutic applications. The application, filed by Institute of Science Tokyo and Nissan Chemical Corporation, covers novel artificial nucleic acid structures with potential pharmaceutical and therapeutic uses, classified under A61P (therapeutic activity) and A61K (preparations for medical use). The A1 publication includes the European search report and is effective as of April 8, 2026.\n\nThird parties should review the published claims and monitor the EPO Register for examination results. The patent application designates 31 European states, meaning any eventual granted patent could create exclusive rights across multiple EU and EEA countries. Competitors developing similar nucleic acid technologies should assess potential freedom-to-operate implications.